Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

EMBO molecular medicine - 1 Mar 2018

Jurmeister Sarah, Ramos-Montoya Antonio, Sandi Chiranjeevi, Pértega-Gomes Nelma, Wadhwa Karan, Lamb Alastair D, Dunning Mark J, Attig Jan, Carroll Jason S, Fryer Lee Gd, Felisbino Sérgio L, Neal David E

Abstract excerpt

Genetically engineered mouse models of cancer can be used to filter genome-wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumours arising in two established mouse models of prostate cancer, PB-Cre/PtenloxP/loxP and p53loxP/loxPRbloxP/loxP, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Naphthyridines

Share to Neoplasm Invasiveness

Share to Prostatic Neoplasms

Share to Spindle Apparatus

Share to Stathmin

Source

Open in PubMed Open full text

Identifiers

PMID: 29437778
DOI: 10.15252/emmm.201708274
PMCID: PMC5840539

Genes

MELK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of potential therapeutic targets in prostate cancer through a cross-species approach.PMID 29437778Read ↗

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerSemantic proximity Read ↗

Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapySemantic proximity Read ↗

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerSemantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-lossSemantic proximity Read ↗

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancerSemantic proximity Read ↗

Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasisSemantic proximity Read ↗

Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity.Semantic proximity Read ↗

ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilitiesSemantic proximity Read ↗

PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.Semantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

<em>In Vivo </em>Models for Prostate Cancer ResearchSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.